Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2011 1
2012 1
2013 1
2015 1
2016 1
2017 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.
McDonnell SR, Hwang SR, Basrur V, Conlon KP, Fermin D, Wey E, Murga-Zamalloa C, Zeng Z, Zu Y, Elenitoba-Johnson KS, Lim MS. McDonnell SR, et al. Oncogene. 2012 Aug 9;31(32):3733-40. doi: 10.1038/onc.2011.542. Epub 2011 Dec 19. Oncogene. 2012. PMID: 22179823 Free PMC article.
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR. Zou HY, et al. Among authors: mcdonnell sr. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. doi: 10.1073/pnas.1420785112. Epub 2015 Mar 2. Proc Natl Acad Sci U S A. 2015. PMID: 25733882 Free PMC article.
Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.
Hwang SR, Murga-Zamalloa C, Brown N, Basappa J, McDonnell SR, Mendoza-Reinoso V, Basrur V, Wilcox R, Elenitoba-Johnson K, Lim MS. Hwang SR, et al. Among authors: mcdonnell sr. Lab Invest. 2017 Aug;97(8):962-970. doi: 10.1038/labinvest.2017.39. Epub 2017 Apr 17. Lab Invest. 2017. PMID: 28414323
Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma.
McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, Fermin D, Wolfe T, Raskind A, Ruan C, Jiang JK, Thomas CJ, Hogaboam CM, Burant CF, Elenitoba-Johnson KS, Lim MS. McDonnell SR, et al. Blood. 2013 Aug 8;122(6):958-68. doi: 10.1182/blood-2013-01-482026. Epub 2013 Jun 27. Blood. 2013. PMID: 23814019 Free PMC article.
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. Zou HY, et al. Among authors: mcdonnell sr. Cancer Res. 2007 May 1;67(9):4408-17. doi: 10.1158/0008-5472.CAN-06-4443. Cancer Res. 2007. PMID: 17483355 Free article.
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Christensen JG, et al. Among authors: mcdonnell sr. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. doi: 10.1158/1535-7163.MCT-07-0365. Mol Cancer Ther. 2007. PMID: 18089725 Free article.
Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, Briscoe CP. Cho H, et al. Among authors: mcdonnell sr. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1142-51. doi: 10.1152/ajpendo.90298.2008. Epub 2008 Aug 26. Am J Physiol Endocrinol Metab. 2008. PMID: 18728225 Free article.